Effects of the genetic polymorphism CYP2 C19 on pharmacokinetics of citalopram in Chinese healthy volunteers
- VernacularTitle:CYP2 C19遗传多态性对中国健康受试者西酞普兰代谢的影响
- Author:
Li-Juan ZHANG
1
;
Fang TIAN
Author Information
1. 军事医学科学院附属医院 临床药理学研究室
- Keywords:
citalopram;
CYP2C19;
genetic polymorphism;
HPLC -MS/MS;
pharmacokinetic
- From:
The Chinese Journal of Clinical Pharmacology
2014;(4):324-326,331
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effets of cytochrome CYP2C19 gene polymorphism on the pharmacokinetics of citalopram in Chinese healthy male volunteers.Methods Twenty-four Chinese healthy male volunteers were orally administered with a single dose of citalopram 20 mg.The venous blood samples were collected , using anticoagulantion EDTA to extract DNA, and the genotype was detected .The blood sam-ples(5 mL) from the bolunteers were collected before and after the ad-ministration of citalopram and plasma was taken .The plasma concentra-tion of citalopram was examined by HPLC -MS/MS method .The geno-type CYP2 C19 was measured by PCR -based sequencing.The measure-ments were performed by HPLC -MS/MS.Pharmacokinetic differences of citalopram on patients with different genotypes were compared .Results Two out of 24 volunteers were poor metabolizing genotype ( PM ) , and 22 were extensive metabolizers (EM).Among the EM 12 were homozy-gotes and 10 were heterozygotes.The pharmacokinetic of citalopram was largely influenced by CYP2 C19 genetic polymorphism , and also effected by the volunteers′age and weight.Conclusion The CYP2 C19 genotype of patients should be detected before the clinical appliaction of citalo-pram, and the age as well as weight also need to be considered .
